Research Center for Persian Medicine and History of Medicine, Shiraz University of Medical Sciences, Shiraz 7134845794, Iran.
Medicinal Plants Processing Research Center, Shiraz University of Medical Sciences, Shiraz 7134845794, Iran.
J Integr Med. 2020 Sep;18(5):401-408. doi: 10.1016/j.joim.2020.06.003. Epub 2020 Jun 15.
Obesity is a major public health problem and its occurrence is markedly increasing in developed and developing countries. However, few studies have investigated the use of natural products to treat obesity. The effects of taking a combination of oxymel and Zataria multiflora Boiss. (ZM), herein referred to as Zataria oxymel (ZO), on obesity, lipid profile and insulin resistance have not yet been studied.
This study evaluates the effects of oxymel and ZO on obesity, lipid profile and insulin resistance.
DESIGN, SETTING, PARTICIPANTS AND INTERVENTIONS: In this randomized, controlled, triple-blind trial, overweight patients were randomly divided into three groups and received doses of study compounds twice per day for twelve weeks. Group A received 0.75 g ZM in 10 mL oxymel in each treatment; group B received 1.5 g ZM in 10 mL of oxymel in each treatment and group C (control) only received 10 mL of oxymel in each treatment.
Anthropometric parameters, including body mass index (BMI), waist circumference and hip circumference, were measured at the time of registration. Blood tests were carried out at the beginning and once again at end of the study. Blood parameters included fasting blood sugar (FBS), insulin levels, serum lipid profile (total cholesterol, triglyceride, low-density lipoprotein cholesterol and high-density lipoprotein cholesterol) and liver enzymes (aspartate transaminase and alanine transaminase). Serum creatinine was also measured at the beginning of the project and in monthly intervals for three months. The homeostasis model assessment index was calculated as fasting insulin (μIU/mL) × FBS (mg/dL)/405.
The results showed that patients receiving ZO experienced significant reduction in waist circumference in groups A, B and C, respectively (P < 0.001) but no significant change in BMI. Group A also experienced reduction in hip circumference (P = 0.01). Groups B and C had reduction in the homeostatic model assessment of insulin resistance (P = 0.05 and P = 0.01, respectively), with no significant reduction in FBS. No effect on lipid profile, liver enzymes or serum creatinine was observed in the three groups.
In this study, treatment with ZO and oxymel reduced insulin resistance, and waist and hip circumferences in overweight patients. Nonetheless, the traditional Persian use of ZO as a beverage to improve the anthropometric indices in overweight individuals still requires further research with a larger sample size.
Iranian Registry of Clinical Trials Code IRCT20171220037976N1.
肥胖是一个主要的公共卫生问题，其发生在发达国家和发展中国家都明显增加。然而，很少有研究调查使用天然产物来治疗肥胖。服用混合蜂蜜酒和香青兰（ZM）的组合（以下称为香青兰蜂蜜酒，ZO）对肥胖、血脂谱和胰岛素抵抗的影响尚未得到研究。
本研究评估了蜂蜜酒和 ZO 对肥胖、血脂谱和胰岛素抵抗的影响。
设计、地点、参与者和干预措施：在这项随机、对照、三盲试验中，超重患者被随机分为三组，每天接受两次研究化合物的剂量，持续 12 周。A 组接受每次治疗中 0.75 克 ZM 在 10 毫升蜂蜜酒中；B 组接受每次治疗中 1.5 克 ZM 在 10 毫升蜂蜜酒中，而 C 组（对照组）仅在每次治疗中接受 10 毫升蜂蜜酒。
在登记时测量人体测量参数，包括体重指数（BMI）、腰围和臀围。在研究开始时和再次进行一次血液检查。血液参数包括空腹血糖（FBS）、胰岛素水平、血清血脂谱（总胆固醇、甘油三酯、低密度脂蛋白胆固醇和高密度脂蛋白胆固醇）和肝酶（天门冬氨酸转氨酶和丙氨酸转氨酶）。在项目开始时和接下来的三个月中每月测量一次血清肌酐。稳态模型评估指数计算为空腹胰岛素（μIU/mL）× FBS（mg/dL）/405。
结果表明，接受 ZO 治疗的患者分别在 A、B 和 C 组中腰围显著减少（P<0.001），但 BMI 无显著变化。A 组也减少了臀围（P=0.01）。B 组和 C 组的胰岛素抵抗稳态模型评估均减少（P=0.05 和 P=0.01），但 FBS 无显著减少。三组患者的血脂谱、肝酶或血清肌酐均无变化。
在这项研究中，ZO 和蜂蜜酒的治疗降低了超重患者的胰岛素抵抗和腰围和臀围。然而，传统的波斯人将 ZO 作为一种饮料来改善超重个体的人体测量指标，仍需要更大样本量的进一步研究。
伊朗临床试验注册中心代码 IRCT20171220037976N1。
